Endocrine Abstracts

Introduction: Diabetes is the most common endocrine disease in the world. Persistent hyperlipidemia in type 2 diabetes is accompanied by damage to various organs, on the basis of which generalized changes in the microvasculature lie. In patients with diabetes mellitus with chronic kidney disease, dyslipidemia can be aggravated with hyperglycemia and insulin resistance. Control of dyslipidemia is an important therapeutic goal, since normalization of lipid metabolism and glycemic status reduces the risk of renal complications in type 2 diabetes. Aim of the work to study lipid metabolism in patients with type 2 diabetes mellitus with diabetic nephropathy.

Materials and methods: The study included 50 patients with type 2 diabetes. Group 1 of 25 patients with type 2 diabetes mellitus did not have a history of diabetic nephropathy; Group 2 of 25 patients had chronic kidney disease (CKD-C2, A2) with type 2 diabetes. The median age was 52.7 ± 3.78 years: type 2 diabetes was 8 years: BMI-27.6: Hb1C-10.5%: Fasting glycemia – 8.8 mmol/l.

Results: Dyslipidemia was observed in 37% of type 2 diabetes without CKD and 78% of type 2 diabetes with CKD. Patients with atherogenic VLDL dyslipidemia, a high level of TG + VLDL was 25% among patients with type 2 diabetes and 71% among patients with type 2 diabetes with CKD. GFR in patients with type 2 diabetes was 89 ml/min, patients with type 2 diabetes with GFR 65 ml/min.

Conclusion: According to our results, we can conclude that lipid metabolism is significantly impaired among patients with diabetic nephropathy. Depending on the course of CKD, lipid metabolism is also exacerbated. Regular screening of diabetic nephropathy with dyslipidemia can be useful for controlling the risk of macrovascular complications.